These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34590480)

  • 21. Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors?
    Chatterjee P; Botello-Smith WM; Zhang H; Qian L; Alsamarah A; Kent D; Lacroix JJ; Baudry M; Luo Y
    J Am Chem Soc; 2017 Dec; 139(49):17945-17952. PubMed ID: 29124934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the Role of Chemical Reactions in the Selectivity of Tyrosine Kinase Inhibitors.
    Asadi M; Xie WJ; Warshel A
    J Am Chem Soc; 2022 Sep; 144(36):16638-16646. PubMed ID: 36044733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.
    Qiu H; Liu-Bujalski L; Caldwell RD; Viacava Follis A; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones CCV; Jones R; Mochalkin I; Morandi F; Neagu C; Potnick J; Sherer B
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3307-3311. PubMed ID: 30243592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with α-Substituent Electrophiles Targeting Cysteine.
    Ai Y; Yang Z; Yang Z; Wan S; Huang C; Huang C; Li M; Li Z; Zhang J; Zhang T
    J Chem Inf Model; 2023 Jan; 63(2):493-506. PubMed ID: 36632804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.
    Sun SL; Wu SH; Kang JB; Ma YY; Chen L; Cao P; Chang L; Ding N; Xue X; Li NG; Shi ZH
    J Med Chem; 2022 Jun; 65(11):7415-7437. PubMed ID: 35594541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton's Tyrosine Kinase.
    Harris CM; Foley SE; Goedken ER; Michalak M; Murdock S; Wilson NS
    SLAS Discov; 2018 Dec; 23(10):1040-1050. PubMed ID: 29991334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
    Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
    J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
    J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.
    Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Babu Boga S; Alhassan AB; Yu W; Selyutin O; Yu Y; Anand R; Xu J; Kelly J; Duffy JL; Liu S; Yang C; Wu H; Cai J; Bennett C; Maloney KM; Tyagarajan S; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Zhang-Hoover J; Knemeyer I; Garlisi CG; Stivers P; Brandish PE; Hicks A; Kim R; Kozlowski JA
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127390. PubMed ID: 32738973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
    Pulz R; Angst D; Dawson J; Gessier F; Gutmann S; Hersperger R; Hinniger A; Janser P; Koch G; Revesz L; Vulpetti A; Waelchli R; Zimmerlin A; Cenni B
    ACS Med Chem Lett; 2019 Oct; 10(10):1467-1472. PubMed ID: 31620235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
    Zuo Y; Shi Y; Li X; Teng Y; Pan Z
    Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MD-Based Assessment of Covalent Inhibitors in Noncovalent Association Complexes: Learning from Cathepsin K as a Test Case.
    Endres E; Yuan Chen N; Sotriffer C
    J Chem Inf Model; 2023 May; 63(10):3186-3197. PubMed ID: 37165835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking.
    Zhang H; Jiang W; Chatterjee P; Luo Y
    J Chem Inf Model; 2019 May; 59(5):2093-2102. PubMed ID: 30763080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
    Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide-Based Covalent Inhibitors Bearing Mild Electrophiles to Target a Conserved His Residue of the Bacterial Sliding Clamp.
    Compain G; Monsarrat C; Blagojevic J; Brillet K; Dumas P; Hammann P; Kuhn L; Martiel I; Engilberge S; Oliéric V; Wolff P; Burnouf DY; Wagner J; Guichard G
    JACS Au; 2024 Feb; 4(2):432-440. PubMed ID: 38425897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bicyclobutane Carboxylic Amide as a Cysteine-Directed Strained Electrophile for Selective Targeting of Proteins.
    Tokunaga K; Sato M; Kuwata K; Miura C; Fuchida H; Matsunaga N; Koyanagi S; Ohdo S; Shindo N; Ojida A
    J Am Chem Soc; 2020 Oct; 142(43):18522-18531. PubMed ID: 33047956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
    Yang Y; Shu YZ; Humphreys WG
    Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
    Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
    Watterson SH; Liu Q; Beaudoin Bertrand M; Batt DG; Li L; Pattoli MA; Skala S; Cheng L; Obermeier MT; Moore R; Yang Z; Vickery R; Elzinga PA; Discenza L; D'Arienzo C; Gillooly KM; Taylor TL; Pulicicchio C; Zhang Y; Heimrich E; McIntyre KW; Ruan Q; Westhouse RA; Catlett IM; Zheng N; Chaudhry C; Dai J; Galella MA; Tebben AJ; Pokross M; Li J; Zhao R; Smith D; Rampulla R; Allentoff A; Wallace MA; Mathur A; Salter-Cid L; Macor JE; Carter PH; Fura A; Burke JR; Tino JA
    J Med Chem; 2019 Apr; 62(7):3228-3250. PubMed ID: 30893553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.